ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

DRTS Alpha Tau Medical Ltd

3.10
0.00 (0.00%)
Pre Market
Last Updated: 13:50:09
Delayed by 15 minutes
Share Name Share Symbol Market Type
Alpha Tau Medical Ltd NASDAQ:DRTS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 3.10 3.00 3.15 75 13:50:09

Alpha Tau to Present at the 43rd Annual J.P. Morgan Healthcare Conference

11/12/2024 1:30pm

GlobeNewswire Inc.


Alpha Tau Medical (NASDAQ:DRTS)
Historical Stock Chart


From Nov 2024 to Dec 2024

Click Here for more Alpha Tau Medical Charts.

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CEO Uzi Sofer and CFO Raphi Levy will present a corporate overview and update at the J.P. Morgan 43rd Annual Healthcare Conference on Thursday, January 16, 2025 at 9:45am PT / 12:45pm ET, in San Francisco, CA, and will host institutional investor meetings at the event.

Event:J.P. Morgan 43rd Annual Healthcare Conference
Format:Presentation and 1-on-1 Meetings
Date:January 16, 2025
Time:9:45AM PT – 10:25AM PT
Location:Westin St. Francis, San Francisco, CA

Webcast: Link located on the “Events & Presentations” page in the Investor Relations section on the Company’s website at https://www.alphatau.com/events

Please reach out to your J.P. Morgan representative to schedule 1-on-1 meetings with Mr. Sofer and Mr. Levy.

About Alpha Tau Medical Ltd.

Founded in 2016, Alpha Tau is an Israeli oncology therapeutics company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.

About Alpha DaRT®

Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.

Investor Relations Contact: IR@alphatau.com

1 Year Alpha Tau Medical Chart

1 Year Alpha Tau Medical Chart

1 Month Alpha Tau Medical Chart

1 Month Alpha Tau Medical Chart

Your Recent History

Delayed Upgrade Clock